ArticleVeterinary sciences2026
Validation of Recombinant Type I Interferon Antiviral Activity Against Porcine Epidemic Diarrhea Virus In Vitro and In Vivo.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine epidemic diarrhea virus (PEDV), a coronavirus responsible for severe watery diarrhea in neonatal piglets, leads to significant economic losses globally. Effective prevention and treatment of PEDV infection is critical to the swine industry. Currently, there are no available therapeutic drugs for PEDV. Porcine interferons (poIFNs) have been identified as promising molecules against a series of swine viruses due to their broad-spectrum antiviral and immunomodulatory properties. In this study, we demonstrated that type I interferon-α (IFN-α) offered both prophylactic and therapeutic benefits against PEDV infection. Recombinant poIFN-α produced by a prokaryotic expression system was purified through affinity chromatography, and its prophylactic and therapeutic effects against PEDV infection were evaluated in vitro and in vivo through RT-qPCR, clinical symptom monitoring, and pathological examination. In vitro studies revealed a strong antiviral activity of poIFN-α against PEDV in Vero E6 cells, with a more pronounced prophylactic effect compared to therapeutic outcomes. In vivo studies showed that poIFN-α significantly alleviated clinical diarrhea in PEDV-infected piglets and reduced intestinal viral loads. These findings suggest that poIFN-α holds considerable promise as an antiviral agent for PEDV and provides a foundation for the development of therapeutic strategies targeting this virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.